患者衍生异种移植模型市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按肿瘤类型、类型、最终用户、地区和竞争细分

2022 年，全球患者来源异种移植模型市场价值为 3.4519 亿美元，预计在预测期内将强劲增长，到 2028 年复合年增长率为 11.09%。患者来源异种移植 (PDX) 模型市场正在经历快速扩张其增长率为 11.09%。患者来源异种移植 (PDX) 模型市场正在经历快速扩张其增长率在推动癌症研究和个人化医疗方面的关键作用推动了这一发展。 PDX 模型将人类肿瘤组织植入免疫缺陷小鼠体内，为研究癌症生物学和药物开发提供了一个复杂的临床相关平台。近年来，癌症研究取得了长足的进步，这要归功于创新技术和模型，帮助科学家更好地了解疾病并开发更有效的治疗方法。患者来源的异种移植（PDX）模型是一种在癌症研究中受到重视的模型。 PDX 模型正在彻底改变我们的癌症研究方法，提供更准确的人类肿瘤表征并实现个人化医学突破。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	3.4519亿美元
2028 年市场规模	6.468亿美元
2023-2028 年复合年增长率	11.09%
成长最快的细分市场	小鼠模型
最大的市场	北美洲

癌症发生率上升和医疗需求未被满足

PDX 模型市场成长的主要驱动力之一是全球癌症发生率的增加。根据世界癌症研究基金会的数据，癌症是全世界死亡的主要原因，预计未来二十年新病例将增加约 70%。这种令人震惊的趋势迫切需要更有效的癌症治疗。 PDX 模型忠实地复製了人类肿瘤的复杂性和异质性，有助于开发新疗法。它们为研究人员提供了一个平台来研究癌症的各个方面，从肿瘤生物学到药物反应，最终有助于发现更有效的治疗方案。癌症长期以来一直是全球最重大的健康挑战之一，每年影响数百万人的生命。患者来源的异种移植模型是一种临床前研究工具，涉及将人类肿瘤组织植入免疫缺陷小鼠体内。这些小鼠随后会发育出在遗传和分子特征、异质性和生长模式方面与原始人类肿瘤非常相似的肿瘤。 PDX 模型比传统细胞系模型具有多种优势，特别是在癌症发生率上升和医疗需求未满足的背景下。由于人口老化、不健康的生活方式和环境污染等多种因素，全球癌症发生率不断上升。 PDX 模型维持了患者肿瘤中发现的细胞类型的复杂组合，使其成为研究肿瘤异质性、疾病进展和治疗抗药性发展的宝贵资源。这反映了癌症的临床现实，个别患者通常具有不同的肿瘤特征。

PDX 技术的进步

PDX 技术的不断进步显着提高了这些模型的可靠性和多功能性。源自患者的类器官（能够更准确地模拟人类肿瘤的三维细胞培养物）的开发扩大了 PDX 模型的应用范围。类器官可用于以高通量方式研究药物反应，对于精准医疗工作特别有价值。此外，植入技术的改进解决了与低植入率相关的一些挑战，提高了 PDX 模型的整体实用性。随着 PDX 技术的不断发展，其对研究人员和行业利益相关者的吸引力不断增长。

传统的 PDX 模型需要立即将患者肿瘤组织移植到小鼠体内。然而，冷冻保存技术的最新进展使得可以长期保存源自患者的样本。这项突破不仅使物流变得更加容易，而且使研究人员能够建立代表多种癌症类型和亚型的 PDX 模型储存库。移植技术的进步提高了PDX模型建立的成功率。研究人员现在可以以更高的成功率移植较小的组织样本，从而减少对大量患者材料的需求。在处理珍贵或有限的活检样本时，这一点尤其重要。虽然传统的 PDX 模型使用免疫功能低下的小鼠，但最近的进展导致了具有人源化免疫系统的 PDX 模型的开发。这些模型更准确地表示了肿瘤与人类免疫系统之间的相互作用，使其对于免疫疗法的研究和开发具有无价的价值。

生物标记发现和药物开发

PDX 模型为生物标记发现提供了独特的机会，这对于开发标靶癌症疗法至关重要。研究人员可以研究 PDX 肿瘤的分子和遗传特征，以确定与药物反应和抗药性相关的新生物标记。这些知识对于设计更有效、有针对性的疗法来改善患者的治疗效果非常宝贵。生物标誌物驱动的药物开发正在蓄势待发，而 PDX 模型处于这些努力的最前线。患者来源的异种移植（PDX）模型是癌症研究和药物开发的强大工具。 PDX 模型是透过将患者的肿瘤细胞移植到小鼠或其他动物体内而创建的。这使得研究人员能够在更自然的环境中研究肿瘤，并在比传统体外模型更相关的环境中测试新药。 PDX 模型越来越多地用于发现和验证癌症生物标记。生物标记是可用于识别、诊断或监测疾病的生物分子。 PDX 模型可用于识别特定癌症类型的生物标记或预测患者对治疗反应的生物标记。 PDX 模型也被用来开发癌症新药。 PDX 模型可用于筛选新药的有效性和安全性。它们还可用于研究药物的作用机制并确定比单一药物更有效的药物组合。

PDX 模型采用激增背后最重要的驱动力之一是其促进生物标记发现的能力。生物标记是可测量的生物指标，可提供有关疾病进展、治疗反应和预后的重要资讯。识别和验证生物标记对于了解疾病机制和针对个别患者制定治疗方案至关重要。 PDX 模型在这方面具有独特的优势，因为它们密切复製了人类肿瘤的分子和细胞特征，使研究人员能够在体内环境中研究疾病途径、基因突变和蛋白质表现。

主要市场挑战

异质性和变异性

PDX 模型的主要挑战之一是人类肿瘤固有的异质性和变异性。人类癌症具有高度多样性，即使在同一癌症类型中也是如此，因此很难创建准确代表疾病各个方面的 PDX 模型。肿瘤异质性可能导致药物反应的变化，使得仅基于 PDX 模型预测疗法的有效性变得具有挑战性。这种限制可能会阻碍临床前结果转换成临床结果的。人类癌症因其多样性而臭名昭着，即使是同一类型或亚型的肿瘤也是如此。这种多样性源自于基因突变、细胞组成、微环境因素和许多其他复杂的生物学方面的变化。因此，创建忠实代表整个异质性的 PDX 模型成为一项艰鉅的任务。挑战在于从患者身上选择一小块肿瘤组织，将其移植到免疫缺陷小鼠体内，并期望它能准确地反映原始肿瘤的复杂性。虽然 PDX 模型确实捕捉了这种多样性的许多方面，但它们无法完全复製患者肿瘤内发生的全部基因突变和细胞相互作用。

时间和资源强度

PDX 模型的产生和维护是一个耗时且资源密集的过程。建立单一 PDX 模型可能需要几个月的时间，包括初始植入、扩展和表征阶段。此外，PDX 模型需要持续监控和维护，从而增加了营运成本。这种时间和资源强度会限制 PDX 模型研究的可扩展性，特别是对于预算和资源有限的学术和小型研究机构。建立和维护 PDX 模型是一个费力且耗时的过程。它通常从将患者肿瘤组织移植到免疫缺陷小鼠开始。虽然最初的植入阶段可能需要几週的时间，但这只是漫长旅程的开始。 PDX 模型需要持续监测，包括追踪肿瘤生长、评估治疗反应以及管理小鼠的健康和福祉。这种持续的关注和监督增加了营运成本并消耗了研究人员宝贵的时间。

成本和可近性

建立和维护 PDX 模型的成本可能很高，特别是对于预算有限的机构。与获取免疫缺陷小鼠、饲养和照顾它们以及进行实验相关的成本可能成为许多研究人员进入的障碍。此外，处理 PDX 模型所需的专用设备和专业知识也增加了整体成本。高额的前期投资和持续开支可能会限制 PDX 模型向更广泛的研究界的开放。创建和维护 PDX 模型是一项昂贵的工作。它包含几个昂贵的组成部分，包括获取免疫缺陷小鼠、在受控环境中饲养和照顾它们、获取患者肿瘤样本以及进行实验。对于许多学术机构、小型研究组织和预算有限的新兴生物技术公司来说，前期投资和持续的营运费用可能导致 PDX 模型无法负担。 PDX 模式的高成本造成了可近性的差异，限制了其主要向资金雄厚的研究机构和大型製药公司提供。

主要市场趋势

对个人化医疗的兴趣日益浓厚

个人化医疗，即根据患者的基因组成和特定疾病特征为个别患者量身定制治疗方案，正在获得发展势头。 PDX 模型透过提供一个针对患者特定肿瘤样本测试疗法的平台，在这项范式转移中发挥关键作用。利用来自个别患者的肿瘤创建「阿凡达小鼠」的能力可以更准确地预测治疗反应，降低不良反应的风险并优化治疗结果。 PDX 模式非常适合支援个人化医疗的原则。透过将患者肿瘤组织直接移植到免疫缺陷小鼠体内，研究人员可以创造出携带来自个别患者的肿瘤的「阿凡达小鼠」。这些模型忠实地复製了原始肿瘤的遗传和分子复杂性，从而可以对潜在疗法进行高度个人化的临床前测试。因此，PDX 模型使研究人员能够预测个别患者的肿瘤对特定治疗的反应，为更有效和更有针对性的治疗铺平道路。

个人化医疗的好处是多方面的。患者将从不仅更有效而且不太可能产生不良副作用的治疗中获益，因为治疗可以根据他们的遗传和分子特征进行客製化。製药公司透过提高临床试验的成功率和减少历史上困扰药物开发的昂贵的后期失败而受益。

基因组分析的进展

基因组定序技术以惊人的速度发展，使研究人员能够更深入地研究肿瘤的遗传和分子基础。这些丰富的基因组资料正在被整合到 PDX 模型研究中，可以更全面地了解基因突变、生物标记和癌症驱动途径。这种整合透过促进潜在治疗标靶和预测生物标记的识别，增强了 PDX 模型在药物开发中的实用性。此外，基因组分析为识别可指导药物开发的特定生物标记和治疗标靶打开了大门。 PDX 模型与基因组学整合后，将成为验证这些目标并预测患者对新疗法的反应的强大工具。这种预测能力对于降低临床试验期间候选药物的损耗率并确保正确的治疗方法到达正确的患者至关重要。

免疫疗法革命

免疫疗法已成为治疗癌症和其他疾病的突破性方法。 PDX 模型有助于研究肿瘤与免疫系统之间的复杂相互作用。研究人员正在使用这些模型来评估免疫疗法（例如检查点抑制剂和 CAR-T 细胞疗法）的疗效，并探索新型联合疗法。因此，PDX 模型在免疫治疗领域的发展中发挥关键作用。 PDX 模型在研究免疫疗法方面具有独特的优势，因为它们密切模拟体内肿瘤微环境，包括肿瘤细胞和免疫细胞之间的复杂相互作用。研究人员可以使用这些模型来评估免疫疗法在忠实复製人类肿瘤复杂性的环境中的有效性。这种能力对于优化免疫治疗策略、预测患者反应以及识别免疫治疗成功的潜在生物标记至关重要。推动 PDX 模型在免疫疗法研究中采用的关键因素之一是它们创建个人化模型的能力。研究人员可以使用患者特异性肿瘤样本产生 PDX 模型，从而能够测试与个别患者的肿瘤非常相似的肿瘤的免疫疗法。

细分市场洞察

肿瘤类型见解

根据肿瘤类型，乳癌细分市场将在 2022 年成为全球患者来源异种移植模型市场的主导者。这是由于全球乳癌病例不断增加。首先，乳癌是全世界最常见的癌症之一，每年影响数百万人。它的高发病率使其成为研究和药物开发工作的优先事项，推动大量投资以了解其复杂性并确定有效的治疗方法。 PDX 模型已被证明在乳癌研究中特别有价值，因为它们能够忠实地复製患者肿瘤的遗传和分子特征。研究人员可以使用这些模型来研究乳癌亚型的异质性，并测试针对个别患者量身定制的潜在疗法。

模型类型见解

根据模型类型，小鼠模型细分市场将在2022 年成为全球患者来源异种移植模型市场的主导者。这归因于几个关键因素，包括生物学相关性、小鼠模型拥有完善的基础设施以及小鼠模型使研究人员能够在较长时间内进行纵向研究等。小鼠模型密切模仿人类肿瘤的生理和生物学方面，使其成为 PDX 研究的首选。将患者肿瘤组织植入免疫缺陷小鼠体内，研究人员可以重建肿瘤微环境，包括与免疫细胞、基质成分和血管的相互作用。这种生物学相关性对于研究疾病进展和评估潜在疗法的疗效至关重要。

区域洞察

2022年，北美成为全球患者来源异种移植模型市场的主导者，占据最大的市场份额。这是由于先进的医疗基础设施、强大的研发生态系统和高度的监管接受度等几个关键因素。北美是包括癌症在内的各种疾病的发生率相对较高的地区，因此需要深入的研究工作并开发更有效的治疗方法。 PDX 模型在肿瘤学研究中发现了特别的相关性，与该地区对癌症治疗和药物发现的关註一致。

北美拥有全球最先进的医疗基础设施之一，拥有最先进的医院、医疗设施和研究机构。这个强大的医疗保健生态系统促进了需要 HGH 治疗的疾病的诊断和治疗，有助于该地区在市场上的突出地位。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球病患衍生异种移植模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依肿瘤类型（肺癌、胰臟癌、摄护腺癌、乳癌、其他癌症）
  • 按类型（小鼠、大鼠）
  • 依最终使用者（住院设定、社区设定）
  • 按公司划分 (2022)
  • 按地区
• 市场地图

第 6 章：北美患者来源的异种移植模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按肿瘤类型
  • 按类型
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲病患来源异种移植模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按肿瘤类型
  • 按类型
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区病患来源的异种移植模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按肿瘤类型
  • 按类型
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲患者来源的异种移植模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按肿瘤类型
  • 按类型
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲病患来源的异种移植模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按肿瘤类型
  • 按类型
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非患者来源的异种移植模型
  • 沙乌地阿拉伯患者来源的异种移植模型
  • 阿联酋病患来源的异种移植模型

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 公司概况
• 产品与服务
• 财务（上市公司）
• 最近的发展
• SWOT分析
  • Charles River Laboratories Inc.
  • The Jackson Laboratory
  • Crown Bioscience,Inc.
  • Altogen Labs
  • Envigo
  • WuxiAppTec
  • Oncodesign
  • Hera BioLabs
  • XenTech
  • Abnova Corporation

第 16 章：策略建议

Global Patient-Derived Xenograft Model Market has valued at USD 345.19 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 11.09% through 2028. The Patient-Derived Xenograft (PDX) Model Market is experiencing a rapid expansion driven by its pivotal role in advancing cancer research and personalized medicine. PDX models, where human tumor tissues are implanted into immunodeficient mice, offer a sophisticated and clinically relevant platform for studying cancer biology and drug development. Cancer research has come a long way in recent years, thanks to innovative techniques and models that help scientists understand disease better and develop more effective treatments. One such model gaining prominence in cancer research is the Patient-Derived Xenograft (PDX) model. PDX models are revolutionizing our approach to cancer studies, offering a more accurate representation of human tumors and enabling personalized medicine breakthroughs.

Patient-Derived Xenograft (PDX) models have gained immense popularity in the realm of preclinical research and drug development. These models, involving the transplantation of patient tumor tissue into immunodeficient mice, closely mimic the complexity of human tumors, offering invaluable insights into disease mechanisms and potential therapeutic strategies. A Patient-Derived Xenograft model involves implanting tumor tissue directly from a cancer patient into an immunodeficient mouse. This model faithfully recapitulates the tumor's genetic and molecular characteristics, as well as its growth patterns and response to therapies. By preserving the original tumor's heterogeneity and complexity, PDX models provide a reliable platform for investigating cancer biology, drug testing, and therapeutic development. Firstly, the rising incidence of cancer worldwide has created an urgent need for more effective treatments. PDX models provide an invaluable tool for testing new cancer therapies, as they faithfully replicate the heterogeneity and complexity of human tumors, allowing researchers to assess drug efficacy and safety more accurately. Secondly, the era of personalized medicine has significantly contributed to the demand for PDX models. Tailoring treatments to individual patients based on their tumor's genetic and molecular characteristics has become a focal point in oncology. PDX models enable researchers and clinicians to predict a patient's response to specific therapies, paving the way for more targeted and effective treatment strategies.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 345.19 Million
Market Size 2028	USD 646.80 Million
CAGR 2023-2028	11.09%
Fastest Growing Segment	Mice Model
Largest Market	North America

Rising Cancer Incidence and Unmet Medical Needs

One of the primary drivers behind the growth of the PDX model market is the global increase in cancer incidence. According to the World Cancer Research Fund, cancer is a leading cause of death worldwide, with new cases expected to rise by approximately 70% over the next two decades. This alarming trend has created an urgent need for more effective cancer treatments. PDX models, which faithfully replicate the complex and heterogeneous nature of human tumors, are instrumental in the development of novel therapies. They provide a platform for researchers to study various aspects of cancer, from tumor biology to drug response, ultimately contributing to the discovery of more effective treatment options. Cancer has long been one of the most significant global health challenges, with millions of lives affected each year. The Patient-Derived Xenograft model is a preclinical research tool that involves the implantation of human tumor tissues into immunodeficient mice. These mice then develop tumors that closely resemble the original human tumors in terms of genetic and molecular characteristics, heterogeneity, and growth patterns. PDX models offer several advantages over traditional cell line models, particularly in the context of rising cancer incidence and unmet medical needs. The global cancer incidence is increasing due to a number of factors, including aging populations, unhealthy lifestyles, and environmental pollution. PDX models maintain the complex mix of cell types found in patient tumors, making them an invaluable resource for studying tumor heterogeneity, disease progression, and the development of treatment resistance. This mirrors the clinical reality of cancer, where individual patients often have diverse tumor profiles.

Advancements in PDX Technology

Continuous advancements in PDX technology have significantly improved the reliability and versatility of these models. The development of patient-derived organoids, three-dimensional cell cultures that more accurately mimic human tumors, has expanded the range of applications for PDX models. Organoids can be used to study drug responses in a high-throughput manner and are particularly valuable for precision medicine efforts. Additionally, improvements in engraftment techniques have addressed some of the challenges associated with low engraftment rates, enhancing the overall utility of PDX models. As PDX technology continues to evolve, its attractiveness to researchers and industry stakeholders continues to grow.

Traditional PDX models required immediate transplantation of patient tumor tissue into mice. However, recent advancements in cryopreservation techniques have allowed for the long-term storage of patient-derived samples. This breakthrough not only facilitates easier logistics but also enables researchers to establish a repository of PDX models representing a wide range of cancer types and subtypes. Enhancements in engraftment techniques have increased the success rates of PDX model establishment. Researchers can now transplant smaller tissue samples with higher success rates, reducing the need for large amounts of patient material. This is particularly crucial when dealing with precious or limited biopsy samples. While traditional PDX models use immunocompromised mice, recent advances have led to the development of PDX models with humanized immune systems. These models offer a more accurate representation of the interactions between tumors and the human immune system, making them invaluable for immunotherapy research and development.

Biomarker Discovery and Drug Development

PDX models offer a unique opportunity for biomarker discovery, which is essential for developing targeted cancer therapies. Researchers can study the molecular and genetic profiles of PDX tumors to identify novel biomarkers associated with drug response and resistance. This knowledge is invaluable for designing more effective, targeted therapies that improve patient outcomes. Biomarker-driven drug development is gaining momentum, and PDX models are at the forefront of these efforts. The patient-derived xenograft (PDX) model is a powerful tool for cancer research and drug development. PDX models are created by transplanting tumor cells from a patient into a mouse or other animal. This allows researchers to study the tumor in a more natural environment and to test new drugs in a more relevant setting than traditional in vitro models. PDX models are increasingly being used to discover and validate biomarkers for cancer. Biomarkers are biological molecules that can be used to identify, diagnose, or monitor a disease. PDX models can be used to identify biomarkers that are specific to a particular cancer type or that are predictive of patient response to treatment. PDX models are also being used to develop new drugs for cancer. PDX models can be used to screen new drugs for efficacy and safety. They can also be used to study the mechanisms of action of drugs and to identify drug combinations that are more effective than single drugs.

One of the most significant driving forces behind the surge in PDX model adoption is its ability to facilitate biomarker discovery. Biomarkers are measurable biological indicators that provide critical information about disease progression, response to therapy, and prognosis. Identifying and validating biomarkers is crucial in understanding disease mechanisms and tailoring treatments to individual patients. PDX models offer a unique advantage in this context as they closely replicate the molecular and cellular characteristics of human tumors, enabling researchers to study disease pathways, genetic mutations, and protein expressions within an in vivo setting.

Key Market Challenges

Heterogeneity and Variability

One of the primary challenges with PDX models is the inherent heterogeneity and variability of human tumors. Human cancers are highly diverse, even within the same cancer type, making it difficult to create PDX models that accurately represent all aspects of the disease. Tumor heterogeneity can result in variations in drug responses, making it challenging to predict the effectiveness of therapies based on PDX models alone. This limitation can hinder the translatability of preclinical results to clinical outcomes. Human cancers are notorious for their diversity, even among tumors of the same type or subtype. This diversity arises from variations in genetic mutations, cellular composition, microenvironmental factors, and many other intricate biological aspects. As a result, creating PDX models that faithfully represent the entirety of this heterogeneity becomes a formidable task. The challenge lies in selecting a small piece of tumor tissue from a patient, engrafting it into immunodeficient mice, and expecting it to accurately mirror the complexity of the original tumor. While PDX models do capture many aspects of this diversity, they cannot fully replicate the full spectrum of genetic mutations and cellular interactions that occur within a patient's tumor.

Time and Resource Intensity

The generation and maintenance of PDX models are time-consuming and resource-intensive processes. It can take several months to establish a single PDX model, including the initial engraftment, expansion, and characterization phases. Furthermore, PDX models require continuous monitoring and care, adding to the operational costs. This time and resource intensity can limit the scalability of PDX model studies, especially for academic and smaller research institutions with limited budgets and resources. Establishing and maintaining PDX models is a laborious and time-consuming process. It typically begins with the transplantation of patient tumor tissue into immunodeficient mice. While this initial engraftment phase can take several weeks, it represents only the beginning of a prolonged journey. PDX models require continuous monitoring, including tracking tumor growth, evaluating treatment responses, and managing the health and well-being of the mice. This ongoing care and oversight add to the operational costs and consume valuable researcher time.

Costs and Accessibility

Establishing and maintaining PDX models can be expensive, particularly for institutions with limited budgets. The costs associated with acquiring immunodeficient mice, housing and caring for them, and conducting experiments can be a barrier to entry for many researchers. Furthermore, the need for specialized equipment and expertise in handling PDX models adds to the overall costs. The high upfront investment and ongoing expenses can limit the accessibility of PDX models to a broader research community. Creating and maintaining PDX models is an expensive endeavor. It encompasses several costly components, including acquiring immunodeficient mice, housing and caring for them in controlled environments, procuring patient tumor samples, and conducting experiments. The upfront investment and ongoing operational expenses can place PDX models out of reach for many academic institutions, smaller research organizations, and emerging biotech companies with constrained budgets. The high costs associated with PDX models create a disparity in accessibility, limiting their availability primarily to well-funded research institutions and large pharmaceutical companies.

Key Market Trends

Rising Interest in Personalized Medicine

Personalized medicine, which tailors medical treatments to individual patients based on their genetic makeup and specific disease characteristics, is gaining momentum. PDX models play a pivotal role in this paradigm shift by offering a platform for testing therapies on patient-specific tumor samples. The ability to create "avatar mice" with tumors derived from individual patients allows for more accurate prediction of treatment responses, reducing the risk of adverse reactions and optimizing therapeutic outcomes. PDX models are uniquely suited to support the principles of personalized medicine. By transplanting patient tumor tissue directly into immunodeficient mice, researchers can create "avatar mice" that carry tumors derived from individual patients. These models faithfully replicate the genetic and molecular complexity of the original tumors, allowing for highly personalized preclinical testing of potential therapies. As a result, PDX models enable researchers to predict how an individual patient's tumor will respond to specific treatments, paving the way for more effective and targeted therapies.

The benefits of personalized medicine are manifold. Patients stand to gain from treatments that are not only more effective but also less likely to produce adverse side effects, as therapies can be tailored to their genetic and molecular profiles. Pharmaceutical companies benefit by increasing the success rates of clinical trials and reducing the costly late-stage failures that have plagued drug development historically.

Advances in Genomic Profiling

Genomic sequencing technologies have advanced at an astonishing pace, enabling researchers to delve deeper into the genetic and molecular underpinnings of tumors. This wealth of genomic data is being integrated into PDX model studies, allowing for a more comprehensive understanding of the genetic mutations, biomarkers, and pathways driving cancer. This integration enhances the utility of PDX models in drug development by facilitating the identification of potential therapeutic targets and predictive biomarkers. Moreover, genomic profiling has opened the door to the identification of specific biomarkers and therapeutic targets that can guide drug development. PDX models, when integrated with genomics, become powerful tools for validating these targets and predicting patient responses to novel treatments. This predictive capability is essential for reducing the attrition rates of drug candidates during clinical trials and ensuring that the right therapies reach the right patients.

Immunotherapy Revolution

Immunotherapy has emerged as a groundbreaking approach in the treatment of cancer and other diseases. PDX models are instrumental in studying the complex interactions between tumors and the immune system. Researchers are using these models to assess the efficacy of immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, and to explore novel combination therapies. PDX models are thus playing a pivotal role in advancing the field of immunotherapy. PDX models offer a unique advantage in studying immunotherapies because they closely mimic the in vivo tumor microenvironment, including the intricate interplay between tumor cells and immune cells. Researchers can use these models to assess the effectiveness of immunotherapies in a setting that faithfully replicates the complexity of human tumors. This capability is critical for optimizing immunotherapeutic strategies, predicting patient responses, and identifying potential biomarkers of immunotherapy success. One of the key factors driving the adoption of PDX models in immunotherapy research is their ability to create personalized models. Researchers can generate PDX models using patient-specific tumor samples, allowing them to test immunotherapies on tumors that closely resemble those of individual patients.

Segmental Insights

Tumor Type Insights

Based on the tumor types, the breast cancer segment emerged as the dominant player in the global market for Patient-Derived Xenograft Model in 2022.This is attributed to increasing breast cancer cases across the world. First and foremost, breast cancer is one of the most prevalent cancers worldwide, affecting millions of individuals each year. Its high incidence has made it a priority for research and drug development efforts, driving significant investments into understanding its complexities and identifying effective treatments. PDX models have proven to be particularly valuable in breast cancer research due to their ability to faithfully replicate the genetic and molecular characteristics of patient tumors. Researchers can use these models to study the heterogeneity of breast cancer subtypes and test potential therapies tailored to individual patients.

Model Type Insights

Based on the model type, the mice model segment emerged as the dominant player in the global market for Patient-Derived Xenograft Model in 2022. This is attributed to several key factors including Biological Relevance, Mice models have a well-established infrastructure, and mice models enable researchers to conduct longitudinal studies over an extended period, etc. Mice models closely mimic the physiological and biological aspects of human tumors, making them a preferred choice for PDX studies. The engraftment of patient tumor tissue into immunodeficient mice allows researchers to recreate the tumor microenvironment, including interactions with immune cells, stromal components, and blood vessels. This biological relevance is essential for studying disease progression and evaluating the efficacy of potential therapies.

Regional Insights

North America emerged as the dominant player in the global Patient-Derived Xenograft Model market in 2022, holding the largest market share. This is on account of several key factors such as advanced healthcare infrastructure, Strong Research and Development Ecosystem and high regulatory acceptance. North America has a relatively high incidence of various diseases, including cancer, which necessitates intensive research efforts and the development of more effective therapies. PDX models have found particular relevance in oncology research, aligning with the region's focus on cancer treatment and drug discovery.

North America boasts one of the most advanced healthcare infrastructures globally, with state-of-the-art hospitals, medical facilities, and research institutions. This robust healthcare ecosystem facilitates the diagnosis and treatment of conditions that require HGH therapy, contributing to the region's prominence in the market.

Key Market Players

• Charles River Laboratories Inc.

• The Jackson Laboratory

• Crown Bioscience,Inc.

• Altogen Labs

• Envigo

• WuxiAppTec

• Oncodesign

• Hera BioLabs

• XenTech

• Abnova Corporation

Report Scope:

In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Patient-Derived Xenograft Model Market, By Tumor Type:

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer

Patient-Derived Xenograft Model Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions

Patient-Derived Xenograft Model Market, By Type:

• Rats
• Mice

Patient-Derived Xenograft Model Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.

Available Customizations:

• Global Patient-Derived Xenograft Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Patient-Derived Xenograft Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer)
  • 5.2.2. By Type (Mice, Rats)
  • 5.2.3. By End-User (Inpatient Settings, Community Settings)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Patient-Derived Xenograft Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Type
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Patient-Derived Xenograft Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End-user
  • 6.3.2. Mexico Patient-Derived Xenograft Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End-user
  • 6.3.3. Canada Patient-Derived Xenograft Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End-user

7. Europe Patient-Derived Xenograft Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Type
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Patient-Derived Xenograft Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End-user
  • 7.3.2. Germany Patient-Derived Xenograft Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End-user
  • 7.3.3. United Kingdom Patient-Derived Xenograft Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End-user
  • 7.3.4. Italy Patient-Derived Xenograft Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End-user
  • 7.3.5. Spain Patient-Derived Xenograft Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End-user

8. Asia-Pacific Patient-Derived Xenograft Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Type
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Patient-Derived Xenograft Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End-user
  • 8.3.2. India Patient-Derived Xenograft Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End-user
  • 8.3.3. South Korea Patient-Derived Xenograft Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End-user
  • 8.3.4. Japan Patient-Derived Xenograft Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tumor Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End-user
  • 8.3.5. Australia Patient-Derived Xenograft Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tumor Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End-user

9. South America Patient-Derived Xenograft Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Type
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Patient-Derived Xenograft Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End-user
  • 9.3.2. Argentina Patient-Derived Xenograft Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End-user
  • 9.3.3. Colombia Patient-Derived Xenograft Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End-user

10. Middle East and Africa Patient-Derived Xenograft Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Type
  • 10.2.3. By End-user
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Patient-Derived Xenograft Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End-user
  • 10.3.2. Saudi Arabia Patient-Derived Xenograft Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End-user
  • 10.3.3. UAE Patient-Derived Xenograft Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Charles River Laboratories Inc.
  • 15.6.2. The Jackson Laboratory
  • 15.6.3. Crown Bioscience,Inc.
  • 15.6.4. Altogen Labs
  • 15.6.5. Envigo
  • 15.6.6. WuxiAppTec
  • 15.6.7. Oncodesign
  • 15.6.8. Hera BioLabs
  • 15.6.9. XenTech
  • 15.6.10. Abnova Corporation

16. Strategic Recommendations